LENZ Stock Plummets 20% as VIZZ Launch Fails to Ignite Market Demand

What happened

LENZ Therapeutics stock fell nearly 20% this week following reports that its recently commercialized presbyopia treatment VIZZ has not generated significant market traction, despite high expectations for the blurry vision therapy. This disappointment stems from the Q4 2025 launch baseline of approximately $1.6M in net product revenue and over 20,000 prescriptions, which set a low bar that the subsequent direct-to-consumer campaign launched in January 2026 has yet to substantially elevate. The stock's fragility is compounded by persistent safety concerns tied to the FDA label's retinal tear/detachment warning, a narrative that continues to overshadow fundamental progress and heighten investor anxiety. According to the DeepValue report, the investment thesis relies critically on VIZZ demand accelerating in Q1-Q2 2026 to leverage the fixed 88-territory sales force and avoid cash burn-driven dilution. The sharp decline now signals market skepticism about near-term revenue growth, forcing LENZ to demonstrate clear commercial momentum in upcoming quarterly updates to restore confidence.

Implication

The stock's 20% drop underscores mounting doubts about VIZZ's ability to scale beyond its initial launch, threatening the fixed-cost commercial model that requires rapid revenue growth to become profitable. With $188.9M in cash as of September 2025, LENZ has a limited runway; prolonged underperformance could force dilutive financing, eroding shareholder value in a weak sentiment environment. Safety overhangs from the retinal risk label persist, and any adverse regulatory updates could further suppress eye care professional adoption, compounding commercial challenges. Investors must closely monitor the imminent Q1 2026 report, where revenue staying at or below $1.5M or prescriptions failing to exceed 50,000 would likely confirm thesis failure and shift probabilities toward the bear case. In that scenario, valuation could compress toward the $7 per share downside target, highlighting the asymmetric risk if VIZZ commercialization stalls while fixed costs burn cash.

Thesis delta

The original thesis posited a potential buy at $12.02 based on expected demand inflection from the January 2026 DTC campaign, but the stock's plunge and lack of market fizz indicate this inflection may be delayed or weaker than anticipated. If Q1 2026 results do not show significant acceleration above the Q4 2025 baseline, the thesis should be downgraded from 'POTENTIAL BUY' to 'HOLD' or 'SELL,' pending evidence of improved execution or safety narrative containment.